Navigation Links
NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon
Date:12/16/2009

CHEVY CHASE, Md., Dec. 16 /PRNewswire/ -- New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced that one of its portfolio companies, Acclarent, Inc., has entered into a definitive agreement to be acquired by Ethicon, Inc., a Johnson & Johnson company, in an all-cash transaction for approximately $785 million (net of estimated cash on hand at time of closing). A medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT), Acclarent was founded by the exclusively NEA-funded ExploraMed incubator in 2004. Today the company's innovative products have been used to treat more than 95,000 patients.

Acclarent's successful outcome exemplifies NEA's pioneering approach to the development of novel medical technologies through incubators like ExploraMed. Acclarent was co-founded by NEA Venture Partner and ExploraMed CEO Josh Makower, MD. Dr. Makower became deeply interested in developing a new treatment option for patients suffering from chronic sinusitis. As he and co-founder John Chang began to build a vision for Acclarent's first approved product--ultimately the company's innovative Balloon Sinuplasty(TM) technology--the incubator model allowed them to execute a proof of concept human clinical study prior to completing a round of financing for the company.

"The incubator model enabled us to focus on clinical needs first and really develop the technology before investing a tremendous amount of capital, energy and human resources in taking the project forward," said Dr. Makower. "With the financial and intellectual resources from NEA, we were able to move through early proof of concept and even into early clinical testing, which enabled us to bring a much more fully developed business plan forward when the time came to raise a significant round of venture capital for Acclarent."

Acclarent went
'/>"/>

SOURCE New Enterprise Associates, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Acclarent, Inc. Closes $26 Million Financing
2. Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
3. Acclarent, Inc. Awarded Red Herring 100 North America
4. Acclarent, Inc. Completes Office-Based Study Using Balloon Sinuplasty(TM) Technology
5. Meritain Health Announces Name Change for Acquired Companies
6. Aspreva to be Acquired by Galenica For US$915 Million
7. Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital-Acquired Infections
8. Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not
9. Microflex(R) Corporation Acquired by Linden and Edgewater
10. MicroActive Corporation Acquired by Linden and Edgewater
11. Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... July 21, 2014 What do romance, ... have in common? You can find them all in ... novel's main character, Miranda, lives on Martha’s Vineyard with ... a wealthy New Yorker, and becomes entangled in a ... Heart challenges readers to think about what choices they ...
(Date:7/21/2014)... (Philadelphia, PA) Patients who have a clot ... be treated with traditional blood-thinning medication or undergo ... comfortable that there is no difference in death ... more bleeding risks with the catheter procedure, according ... Medicine researchers. The study involved a review of ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Executives ... agency specializing in private healthcare practices, will participate ... (IACA). They will be showcasing their state-of-the-art capabilities ... medical practices all over the United States as ... efforts continues to increase. Advice Media’s presence at ...
(Date:7/21/2014)... MONDAY, July 21, 2014 (HealthDay News) -- The "viral ... avoiding detection and elimination, is established much earlier than ... poses new obstacles for those working to eradicate the ... Military HIV Research Program. They said the presence of ... finding a cure for a subtype of HIV, known ...
(Date:7/21/2014)... Public Affairs Research has released the results of a ... means to be a quality health care provider in ... Wood Johnson Foundation, sheds new light on how American ... doctors, as well as the information they use and ... new and actionable data during a crucial period of ...
Breaking Medicine News(10 mins):Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Advice Media to Attend the International Association of Comprehensive Aesthetics Conference (IACA) Targeting the Dental Profession 2Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2
... Central government and striking medicos to end the agitation ... Castes// in educational institutes failed to reach any conclusion ... decision to implement the 27% reservation for OBCs in ... that they would plan to make their agitation 'more ...
... to a study it was found that a number ... measures, like a daily dose of aspirin, colon cancer ... young women, immunizing adults against the flu and pneumonia ... longer and healthier lives. The study’s results were published ...
... Ranbaxy Laboratories Limited today entered into an in-licensing agreement ... (NDDS) analgesic // , Tramadol in the Indian market ... the wholly-owned subsidiary of the French drug major for ... ,The product will be supplied from Ethypharm's manufacturing ...
... Laboratories Limited today said the World Health Organistion has ... products in its pre-qualification list. // ,The ... 200mg capsules, Stavudine 30mg capsules, Stavudine 40mg capsules, the ... significant development. We strongly feel that Generic ARVs are ...
... aroused as fear about childhood obesity grows and thus ... ... child-sized machines, during the past two years. ... Shokk and Zig Zag was building new facilities and installing machines for their little customers. ,According to ...
... Cabinet today cleared the business model for the state-of-the-art Institute ... the capital. // ,The model approved by the ... would enable the institute to be self-sufficient in nine years' ... the finances for procuring medical equipment would be borne by ...
Cached Medicine News:Health News:Disappointed Students Plan To Intensify Agitation Nationwide 2
(Date:7/21/2014)...  An International Trade Commission (ITC) ruling issued Friday ... device, Taiwanese device manufacturer APEX continues to infringe ResMed ... ) is the innovation leader and pioneer in designing ... "Our research and development teams are ... of comfort, performance and efficacy," said David Pendarvis ...
(Date:7/21/2014)... Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... announces that the United States International Trade Commission (USITC) ... newly designed XT series continuous positive airway pressure (CPAP) ... the patent claims asserted by ResMed, one of Apex,s ... an upgraded iCH water tank to the market in ...
(Date:7/18/2014)... 2014 Hanger, Inc. (NYSE: HGR ) ... operations for the quarter ended June 30, 2014, on Tuesday, ... to discuss these results is scheduled to begin at 9:00 ... participate should call 1-877-662-6095. A replay will be available until ... ID # 44683027. About Hanger, Inc. – Built ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
... an international generic pharmaceuticals company, today announced that ... Food & Drug Administration to market Zolpidem Tartrate ... the product has commenced.   Actavis ... Extended-Release Tablets 6.25 mg strength in October 2010 with ...
... 6, 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ... the Phase IB/II study of the Btk inhibitor, PCI-32765, ... (CLL/SLL) at the 2011 American Society of Clinical Oncology ... development program update for the Btk Inhibitor, PCI-32765.  The ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 7Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 8Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 9
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: